SGT 003
Alternative Names: SGT-003Latest Information Update: 20 Aug 2024
At a glance
- Originator Solid Biosciences
- Class Gene therapies
- Mechanism of Action Dystrophin replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 13 Aug 2024 Solid Biosciences files an IND application with Health Canada in Canada for Duchenne muscular dystrophy prior to August 2024
- 13 Aug 2024 The Health Canada approves IND application for SGT 003 in Duchenne muscular dystrophy prior to August 2024
- 13 Aug 2024 Interim adverse events data from a phase I/II INSPIRE DUCHENNE trial in Duchenne muscular dystrophy released by Solid Biosciences